Business Segments — Interest income, net
Vertex Pharmaceuticals Business Segments — Interest income, net decreased by 2.6% to $114.80M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests higher cash balances or improved yields on the segment's investment portfolio, while a decrease may indicate lower cash reserves or a reduced interest rate environment.
Detailed definition
This metric represents the net interest income generated specifically by the financial assets held within the Pharmaceut...
Peer comparison
Comparable to 'Interest and other income' or 'Net interest income' reported by other large-cap biotechnology or pharmaceutical companies, though often dependent on the company's overall treasury management strategy.
vrtx_segment_pharmaceuticals_interest_income_netHistorical Data
| Q1 '25 | Q1 '26 | |
|---|---|---|
| Value | $117.90M | $114.80M |
| QoQ Change | — | -2.6% |
| YoY Change | — | -2.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's business segments — interest income, net?
- Vertex Pharmaceuticals (VRTX) reported business segments — interest income, net of $114.80M in Q1 2026.
- What does business segments — interest income, net mean?
- The net interest earned on cash and investments held by the Pharmaceuticals business segment.